Who is sponsoring NCT02810756?

NCT02810756 is sponsored by The Netherlands Cancer Institute.

What drugs are being tested in NCT02810756?

Interventions in NCT02810756: New Pazopanib formulation.

What condition does NCT02810756 study?

NCT02810756 studies Pharmacokinetics of Pazopanib.

Is NCT02810756 still recruiting?

NCT02810756 is currently completed. Last updated 11 September 2017.

Last reviewed 2017-09-11 · How we verify

NCT02810756

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study With Improved Solubility Pazopanib

Completed EARLY_PHASE1 Last updated 11 September 2017

What this trial tests

EARLY_PHASE1 trial testing New Pazopanib formulation in Pharmacokinetics of Pazopanib in 12 participants. Completed in 28 August 2017.

Timeline

15 September 2016

Primary endpoint
28 August 2017

28 August 2017

Quick facts

Lead sponsor	The Netherlands Cancer Institute
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	15 September 2016
Primary completion	28 August 2017
Estimated completion	28 August 2017
Sites	1 location across Netherlands

Drugs / interventions tested

New Pazopanib formulation — full drug profile →

Conditions studied

Pharmacokinetics of Pazopanib — all drugs for Pharmacokinetics of Pazopanib →

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, any sex, with Pharmacokinetics of Pazopanib. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02810756 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
Last refreshed: 11 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02810756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing